We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

332 hedge funds and large institutions have $4.57B invested in Amicus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 112 increasing their positions, 85 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more funds holding in top 10

Funds holding in top 10: 413 (+9)

120% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 44

86% more capital invested

Capital invested by funds: $2.46B → $4.57B (+$2.11B)

32% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 85

16% more funds holding

Funds holding: 287332 (+45)

2.77% more ownership

Funds ownership: 101.3%104.07% (+2.8%)

19% less call options, than puts

Call options by funds: $18.8M | Put options by funds: $23.1M

Holders
332
Holders Change
+45
Holders Change %
+15.68%
% of All Funds
4.04%
Holding in Top 10
13
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+225%
% of All Funds
0.16%
New
97
Increased
112
Reduced
85
Closed
44
Calls
$18.8M
Puts
$23.1M
Net Calls
-$4.32M
Net Calls Change
-$4.52M
Name Holding Trade Value Shares
Change
Change in
Stake
FRM
351
Fox Run Management
Connecticut
-$553K -70,115 Closed
I
352
InceptionR
California
-$537K -68,134 Closed
XT
353
XTX Topco
Cayman Islands
-$516K -65,467 Closed
Ensign Peak Advisors
354
Ensign Peak Advisors
Utah
-$443K -56,206 Closed
GCP
355
GSA Capital Partners
United Kingdom
-$404K -51,247 Closed
EC
356
EntryPoint Capital
New York
-$389K -49,330 Closed
DnB Asset Management
357
DnB Asset Management
Norway
-$364K -46,161 Closed
HC
358
Henshaw Capital
Massachusetts
-$346K -43,882 Closed
SCP
359
Sender Company & Partners
New York
-$272K -34,540 Closed
BHCM
360
Brevan Howard Capital Management
Jersey
-$246K -31,235 Closed
Thrivent Financial for Lutherans
361
Thrivent Financial for Lutherans
Minnesota
-$236K -29,881 Closed
Truist Financial
362
Truist Financial
North Carolina
-$231K -29,308 Closed
BC
363
Bridgefront Capital
Texas
-$192K -24,418 Closed
SI
364
Stephens Inc
Arkansas
-$149K -18,846 Closed
NSEDCP
365
NJ State Employees Deferred Compensation Plan
New Jersey
-$134K -17,000 Closed
PNC
366
Park National Corp
Ohio
-$129K -16,388 Closed
PA
367
PharVision Advisers
Florida
-$94.5K -11,998 Closed
CM
368
Caption Management
Oklahoma
-$109K -11,100 Closed
TSS
369
Two Sigma Securities
New York
-$85.5K -10,848 Closed
EM
370
ELCO Management
New York
-$79.2K -10,055 Closed
CIBC Private Wealth Group
371
CIBC Private Wealth Group
Georgia
-$11.9K -1,505 Closed
RA
372
Rise Advisors
New York
-$8.98K -1,140 Closed
Bessemer Group
373
Bessemer Group
New Jersey
-$2K -198 Closed
HI
374
Harbour Investments
Wisconsin
-$1.42K -180 Closed
Fifth Third Bancorp
375
Fifth Third Bancorp
Ohio
-$788 -100 Closed

FOLD Hedge Fund Activity: Q4 2025 in Review

332 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2025, worth a combined $4.57B — up 86% from $2.46B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new FOLD positions and 44 closed out — a net gain of 53 holders — while 112 added to existing stakes and 85 trimmed.

The largest buyer was HBK Investments, opening a new position worth an estimated $150M. The largest seller was Wellington Management Group, cutting an estimated $268M.

  • 332 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2025, up from 287 in Q3 2025.
  • Funds reported $4.57B of Amicus Therapeutics stock for Q4 2025, up 86% quarter-over-quarter.
  • 97 funds opened new Amicus Therapeutics positions in Q4 2025 and 44 closed out, a net change of +53 holders.
  • The largest Amicus Therapeutics buyer in Q4 2025 was HBK Investments, an estimated $150M added.
  • The largest Amicus Therapeutics seller in Q4 2025 was Wellington Management Group, an estimated $268M sold.

Based on aggregated 13F filings for Q4 2025.